Can-Fite BioPharma Statistics
Total Valuation
Can-Fite BioPharma has a market cap or net worth of ILS 36.79 million. The enterprise value is 19.21 million.
Market Cap | 36.79M |
Enterprise Value | 19.21M |
Important Dates
The last earnings date was Thursday, November 28, 2024.
Earnings Date | Nov 28, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Can-Fite BioPharma has 2.04 billion shares outstanding. The number of shares has increased by 57.39% in one year.
Current Share Class | n/a |
Shares Outstanding | 2.04B |
Shares Change (YoY) | +57.39% |
Shares Change (QoQ) | n/a |
Owned by Insiders (%) | 0.02% |
Owned by Institutions (%) | 1.94% |
Float | 1.84B |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 11.38 |
PB Ratio | 3.23 |
P/TBV Ratio | 3.94 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -0.69 |
EV / Sales | 7.65 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | -0.69 |
Financial Position
The company has a current ratio of 2.93, with a Debt / Equity ratio of 0.02.
Current Ratio | 2.93 |
Quick Ratio | 2.38 |
Debt / Equity | 0.02 |
Debt / EBITDA | n/a |
Debt / FCF | -0.01 |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -157.62% and return on invested capital (ROIC) is -102.80%.
Return on Equity (ROE) | -157.62% |
Return on Assets (ROA) | -57.46% |
Return on Capital (ROIC) | -102.80% |
Revenue Per Employee | 313,915 |
Profits Per Employee | -3.47M |
Employee Count | 8 |
Asset Turnover | 0.08 |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -33.33% in the last 52 weeks. The beta is 0.61, so Can-Fite BioPharma's price volatility has been lower than the market average.
Beta (5Y) | 0.61 |
52-Week Price Change | -33.33% |
50-Day Moving Average | 2.55 |
200-Day Moving Average | 2.90 |
Relative Strength Index (RSI) | 18.00 |
Average Volume (20 Days) | 38,160,526 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Can-Fite BioPharma had revenue of ILS 2.51 million and -27.75 million in losses. Loss per share was -0.02.
Revenue | 2.51M |
Gross Profit | 2.51M |
Operating Income | -29.34M |
Pretax Income | -27.75M |
Net Income | -27.75M |
EBITDA | -29.31M |
EBIT | -29.34M |
Loss Per Share | -0.02 |
Balance Sheet
The company has 17.80 million in cash and 214,611 in debt, giving a net cash position of 17.59 million or 0.01 per share.
Cash & Cash Equivalents | 17.80M |
Total Debt | 214,611 |
Net Cash | 17.59M |
Net Cash Per Share | 0.01 |
Equity (Book Value) | 9.33M |
Book Value Per Share | 0.01 |
Working Capital | 14.46M |
Cash Flow
In the last 12 months, operating cash flow was -27.98 million and capital expenditures -15,060, giving a free cash flow of -27.99 million.
Operating Cash Flow | -27.98M |
Capital Expenditures | -15,060 |
Free Cash Flow | -27.99M |
FCF Per Share | -0.01 |
Margins
Gross Margin | 100.00% |
Operating Margin | -1,168.37% |
Pretax Margin | -1,105.10% |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
Can-Fite BioPharma does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -57.39% |
Shareholder Yield | -57.39% |
Earnings Yield | n/a |
FCF Yield | n/a |
Stock Splits
The last stock split was on May 12, 2013. It was a reverse split with a ratio of 0.04.
Last Split Date | May 12, 2013 |
Split Type | Reverse |
Split Ratio | 0.04 |
Scores
Can-Fite BioPharma has an Altman Z-Score of -40.01. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -40.01 |
Piotroski F-Score | n/a |